Day: December 18, 2025

Global Cannabis Leader Poised for Major U.S. Market Entry, Signaling New Era for Healthcare NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) — Tilray Medical, a division of Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis healthcare, today confirmed its planned strategic framework to advance its U.S. medical cannabis operations following federal cannabis rescheduling and related regulatory developments. In conjunction with these regulatory changes, Tilray announced the formation of Tilray Medical USA, Inc., further strengthening its commitment to leading medical cannabis innovation and growth. The Company’s approach is grounded in its proven track record operating at scale in regulated medical cannabis markets globally, supported by established compliance systems, scientific...

NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the following statement from CEO Jon Levine today. “We commend President Trump and the Trump Administration for reclassifying cannabis as a Schedule III drug. This is the single greatest cannabis reform in US history and will have far-reaching benefits for years to come. Most important, the reclassification means the Federal government officially acknowledges that cannabis has widely accepted medical uses and low abuse potential. Rescheduling will accelerate accredited medical research into medications derived from cannabis and should result in a significant increase of consumers who will embrace cannabis as a qualified alternative to opioids...

PRESS RELEASE AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext – FR0010557264 – AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm. Maxim Group began covering the stock with a study entitled “Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS”, published on 18 December 2025. In this study, Maxim Group recommended buying the stock, with a target price of €4.00. The study highlights that “Masitinib has generated promising benefits across three neurodegenerative diseases, which we believe validates the mast cell inhibition approach. Considering the underlying efficacy...

Peak Medical, ENvue’s Exclusive Distributor in UK, Places Significant Order after Reimbursement Decision, Projecting Future Market Demand for UroShield® Kit TYLER, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, enabling nationwide prescription reimbursement across the UK. In parallel with this reimbursement milestone, ENvue Medical has secured an initial purchase order from Peak Medical, a leading UK-based distributor specializing in stoma care and urology medical devices with a vast network of hospitals and community settings, reflecting early commercial...

CARBIOS reaffirms its ambition to pursue the Longlaville plant construction project and postpones the timeline by three-month. The plant construction project is supported by:Pre-commercialization contracts covering close to 50% of the production capacity of the future industrial site in Longlaville. Significant progress in structuring the additional financing required to restart the project. Secured public funding of €42.5 million.A small portion1 of the financing still needs to be secured before the project can move forward. CARBIOS aims to achieve this by the end of the first quarter of 2026.With over €55 million in projected available cash at the end of 20252, CARBIOS has visibility on its financing horizon beyond the next twelve months while maintaining its strategic capabilities and a rigorous control over expenses. CARBIOS...

Mundi Énergies launches a network of renewable energy hubs in Canada with Haffner Energy Vitry-le-François, France / Manseau, Quebec, Canada – December 18, 2025, 6:00 p.m. CET/12:00 p.m. EST      Mundi Énergies, a sister company of Machinerie Dubois, becomes the key operator for the development, marketing, and licensed manufacturing of Haffner Energy technologies in Canada. This partnership announced last week aims to establish a vast network of “multi-energy hubs” across the world’s second-largest country, capable of addressing the challenges of energy sovereignty and transition. A strategic alliance with lasting benefits The partnership between Haffner Energy and Mundi Énergies enables: the energy transformation of local residual biomass into high value-added energy resources using Haffner Energy’s thermolysis technology; the acceleration of the...

Extraordinary General Meeting of January 8, 2026Availability of preparatory documents Paris La Défense, December 18, 2025 – The shareholders of Worldline [Euronext: WLN] are convened to an Extraordinary General Meeting on Thursday, January 8, 2026 at 10:00 a.m. (Paris time) at Cloud Business Center – 10 bis rue du Quatre Septembre – 75002 Paris. The meeting notice (avis préalable de réunion) including the agenda, the draft resolutions and the terms and conditions of participation and voting at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) dated December 3, 2025 n°145. The convening notice (avis de convocation) will be published in the BALO dated December 19, 2025. Shareholders are informed that the General Meeting will be broadcast live (in French and English) on the Company’s website...

Press release18 December 2025 – N° 20    SCOR renews its contingent capital program Disclaimer: SCOR (hereafter “SCOR” or the “Company”) has implemented a contingent capital program in the form of share subscription warrants with J.P. Morgan SE, which upon exercise of these warrants after having received the issued shares is not intended to remain a shareholder of the Company. The Company’s ordinary shares, which would result from the exercise of the aforementioned share subscription warrants, will likely be sold on the market very shortly, which may create strong downward pressure on the Company’s share price. Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of the Company’s shares, as well as significant dilution due to the large number of the Company’s...